Sermonix Pharmaceuticals
Ohio llc specialty pharmaceutical.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $40.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Sermonix Pharmaceuticals, founded in 2014 by Dr. David Portman, is a privately held biotechnology company based in Ohio. The company specializes in the development and commercialization of oncology products specifically for women. Sermonix focuses on precision medicine, aiming to bring targeted oncology treatments from development through to approval. The company is currently investigating lasofoxifene, a compound extensively studied for its potential in treating breast and ovarian cancers. Sermonix serves the oncology market, particularly targeting postmenopausal women and premenopausal women undergoing ovarian suppression. The business model involves conducting clinical trials, such as the ELAINE Study, to evaluate the efficacy of their treatments. Revenue is generated through the development and eventual commercialization of these targeted therapies.
Keywords: precision medicine, oncology, female-specific, lasofoxifene, breast cancer, ovarian cancer, clinical trials, biotechnology, targeted treatments, commercialization.